// STATE LEGISLATION TRACKER

Oklahoma HB 1974: Preventative diagnostic services; eligibility; administer; coverage; educational; public awareness; annual report; Legis

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: In committee

State: Oklahoma
Bill: HB 1974
Session: 2025
Filed: 2025-02-03
Read the bill: OpenStates →
Last reviewed: 2026-10-05

Plain-English Summary

Oklahoma HB1974 appears to create or support a preventative diagnostic services program, including eligibility, coverage, public education, and annual reporting. Based on the title, subjects, and listed status only, it does not appear to regulate peptides, compounding pharmacies, off-label prescribing, telehealth, NP/naturopathic scope, controlled substances, or prescription monitoring.

Key Points

No apparent change to compounded peptide access
No apparent change to off-label prescribing rules
No apparent telehealth or scope-of-practice impact
No apparent FDA 503A/503B compounding impact
Peptide users should not expect direct effects

What to Watch For

Note Watch for amendments that add pharmacy, prescribing, or compounding language later.

Note Preventative testing coverage could matter indirectly for general health screening, not peptide access.

Note The bill is early in the process and may change if it advances.

Where the Bill Stands

The bill received a second reading and was referred to the Rules committee, so it has not passed a chamber.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws